JP2018520667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520667A5 JP2018520667A5 JP2017564407A JP2017564407A JP2018520667A5 JP 2018520667 A5 JP2018520667 A5 JP 2018520667A5 JP 2017564407 A JP2017564407 A JP 2017564407A JP 2017564407 A JP2017564407 A JP 2017564407A JP 2018520667 A5 JP2018520667 A5 JP 2018520667A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- heavy chain
- light chain
- variable region
- human antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078441A JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173330P | 2015-06-09 | 2015-06-09 | |
| US62/173,330 | 2015-06-09 | ||
| PCT/US2016/036735 WO2016201124A2 (en) | 2015-06-09 | 2016-06-09 | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078441A Division JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520667A JP2018520667A (ja) | 2018-08-02 |
| JP2018520667A5 true JP2018520667A5 (OSRAM) | 2020-05-28 |
| JP7000162B2 JP7000162B2 (ja) | 2022-02-10 |
Family
ID=57504187
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564407A Expired - Fee Related JP7000162B2 (ja) | 2015-06-09 | 2016-06-09 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
| JP2021078441A Withdrawn JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078441A Withdrawn JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501559B2 (OSRAM) |
| EP (1) | EP3307319A4 (OSRAM) |
| JP (2) | JP7000162B2 (OSRAM) |
| KR (1) | KR20180023949A (OSRAM) |
| CN (1) | CN108289950B (OSRAM) |
| AU (1) | AU2016274767B2 (OSRAM) |
| CA (1) | CA2988768A1 (OSRAM) |
| HK (1) | HK1252653A1 (OSRAM) |
| IL (2) | IL281396B (OSRAM) |
| MX (1) | MX2017015666A (OSRAM) |
| SG (1) | SG10202110887PA (OSRAM) |
| WO (1) | WO2016201124A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
| EP3307319A4 (en) | 2015-06-09 | 2019-05-22 | Memorial Sloan Kettering Cancer Center | T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA |
| AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
| CA3044682A1 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| WO2018200585A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| EP3635000A4 (en) * | 2017-05-16 | 2021-04-14 | The Johns Hopkins University | Manabodies and methods of using |
| CN112041432A (zh) | 2018-02-15 | 2020-12-04 | 纪念斯隆-凯特林癌症中心 | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 |
| WO2019201995A1 (en) | 2018-04-20 | 2019-10-24 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
| CN113423724B (zh) * | 2018-12-27 | 2023-11-24 | 深圳华大生命科学研究院 | Ebv表位高亲和力t细胞受体 |
| CN114144190B (zh) * | 2019-01-23 | 2025-08-08 | 纽约大学 | 对T细胞受体的δ1链具有特异性的抗体 |
| KR20210134091A (ko) * | 2019-01-29 | 2021-11-08 | 그릿스톤 바이오, 인코포레이티드 | 다중특이적 결합 단백질 |
| GB201901306D0 (en) * | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| EP3941491A4 (en) | 2019-03-21 | 2023-03-29 | Gigamune, Inc. | ENGINEERED CELLS EXPRESSING ANTIVIRAL T-CELL RECEPTORS AND METHODS OF USE |
| CA3145857A1 (en) * | 2019-07-03 | 2021-01-07 | Regeneron Pharmaceuticals, Inc. | Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof |
| EP3786178A1 (en) * | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
| WO2021046331A1 (en) * | 2019-09-05 | 2021-03-11 | Memorial Sloan Kettering Cancer Center | Anti-steap1 antibodies and uses thereof |
| WO2021211455A1 (en) * | 2020-04-13 | 2021-10-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against lmp2 |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| CN111690617B (zh) * | 2020-05-18 | 2023-05-02 | 李欣 | 抗eb病毒lmp2a的单克隆抗体及其细胞株和应用 |
| CN114457165A (zh) * | 2022-04-13 | 2022-05-10 | 深圳荻硕贝肯精准医学有限公司 | 一种用于检测hla-a02基因的引物探针组、试剂盒及检测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159982T1 (de) | 1988-09-15 | 1997-11-15 | Univ Columbia | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US6090381A (en) | 1997-02-11 | 2000-07-18 | Immunomedics, Inc. | Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| WO2001037868A1 (en) | 1999-11-24 | 2001-05-31 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| DE60142475D1 (de) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2004041849A1 (en) * | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| CN102812043A (zh) * | 2009-11-19 | 2012-12-05 | 新加坡国立大学 | 用于制备t细胞受体样单克隆抗体的方法及其用途 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2826942C (en) | 2011-02-11 | 2021-08-03 | Memorial Sloan-Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
| JP6082997B2 (ja) | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2015018527A1 (en) | 2013-08-07 | 2015-02-12 | Affimed Therapeutics Ag | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
| WO2015199618A1 (en) | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
| EP3307319A4 (en) | 2015-06-09 | 2019-05-22 | Memorial Sloan Kettering Cancer Center | T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA |
-
2016
- 2016-06-09 EP EP16808304.6A patent/EP3307319A4/en not_active Withdrawn
- 2016-06-09 HK HK18111960.3A patent/HK1252653A1/zh unknown
- 2016-06-09 IL IL281396A patent/IL281396B/en unknown
- 2016-06-09 CN CN201680046924.2A patent/CN108289950B/zh not_active Expired - Fee Related
- 2016-06-09 CA CA2988768A patent/CA2988768A1/en active Pending
- 2016-06-09 JP JP2017564407A patent/JP7000162B2/ja not_active Expired - Fee Related
- 2016-06-09 MX MX2017015666A patent/MX2017015666A/es unknown
- 2016-06-09 SG SG10202110887PA patent/SG10202110887PA/en unknown
- 2016-06-09 WO PCT/US2016/036735 patent/WO2016201124A2/en not_active Ceased
- 2016-06-09 KR KR1020187000659A patent/KR20180023949A/ko not_active Ceased
- 2016-06-09 US US15/735,133 patent/US10501559B2/en active Active
- 2016-06-09 AU AU2016274767A patent/AU2016274767B2/en not_active Ceased
-
2017
- 2017-11-30 IL IL256035A patent/IL256035A/en unknown
-
2019
- 2019-10-28 US US16/665,708 patent/US11168150B2/en active Active
-
2021
- 2021-05-06 JP JP2021078441A patent/JP2021106623A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520667A5 (OSRAM) | ||
| JP7328658B2 (ja) | 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用 | |
| CN108064236B (zh) | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| KR102701479B1 (ko) | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 | |
| BRPI0611194B1 (pt) | Moléculas de ligação anti-cd16 | |
| JP2020508655A5 (OSRAM) | ||
| JP2017526370A5 (OSRAM) | ||
| JP2017537082A5 (OSRAM) | ||
| CN109715661B (zh) | 抗干扰素-γ的抗体及其应用 | |
| JP2012501670A5 (OSRAM) | ||
| KR20130010117A (ko) | Ｂ７―ｈ３에 반응성인 항체, 면역학적으로 활성인 이들의 단편 및 이들의 사용법 | |
| JP2011509245A5 (OSRAM) | ||
| CN110678484B (zh) | 抗pd-l1/抗lag3双特异性抗体及其用途 | |
| Staelens et al. | Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains | |
| JP2019535306A5 (OSRAM) | ||
| JP2019515648A (ja) | ＩＬ７受容体細胞外ドメインα鎖に対する非拮抗性抗体及び癌治療におけるそれらの使用 | |
| JP2016518333A5 (OSRAM) | ||
| CA3157611A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| AU2015336931B2 (en) | CD83 binding proteins and uses thereof | |
| JP2016529213A5 (OSRAM) | ||
| CA3227160A1 (en) | Anti-hla-g antibodies | |
| TW202233677A (zh) | Bcma/taci抗原結合分子 | |
| JPWO2022111425A5 (OSRAM) | ||
| Kapelski et al. | Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a Pf MSP4-specific antibody |